Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore rare renal disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Breakthrough Bleeds
Breakthrough Bleeds

Treatment guidelines for breakthrough bleeds

According to MASAC and WFH guidelines, patients and caregivers need to recognize and treat bleeds rapidly1,2

WFH guidelinesa:

  • Continue to reinforce that patients and caregivers should not take a watch-and-wait approach. Bleeds need to be treated promptly and fully1
  • Note that delayed treatment of bleeding is known to result in worse short- and long-term outcomes in patients with hemophilia1
  • Recommend treating a bleed promptly to:
Check mark icon

Improve bleed resolution1

Check mark icon

Impact the development and long-term progression of arthropathy1

Check mark icon

Reduce rebleeding1

aRefers to the 2020 WFH Guidelines for the Management of Hemophilia, 3rd edition.

Actor portrayal

Treatment conversation illustration

Consider these recommendations from MASAC and the WFH for the treatment of hemophilia A with inhibitors:

  • Despite effective prevention of bleeding episodes with emicizumab, clinicians and patients should still expect breakthrough bleeding3
  • Acute bleeds should be treated promptly3
  • Emicizumab is not intended to treat acute bleeds1

FVIII=factor VIII; ISTH=International Society on Thrombosis and Haemostasis; MASAC=Medical and Scientific Advisory Council; WFH=World Federation of Hemophilia.

Vial and needle icon

Now that you’ve seen the data and guidelines, see a treatment option that may be right for your patients that might experience breakthrough bleeds.

MASAC Guidelines

Review MASAC guidelines that address key areas, including emergency care, treatment recommendations, and management issues concerning patients with hemophilia and other rare bleeding disorders.

National Bleeding Disorders Foundation logo
World Federation of Hemophilia logo

WFH Guidelines

Get the latest information on treatments for hemophilia and rare bleeding disorders, approaches to treating these diseases, and clinical study results.

References:

  1. Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26(suppl 6):1-158.
  2. MASAC recommendation on administration of inhibitor bypassing agents in the home for patients with hemophilia and inhibitors. MASAC Document #274. Accessed December 19, 2022. https://www.hemophilia.org/sites/default/files/document/files/274_HomeAdministration.pdf
  3. MASAC recommendation on the use and management of emicizumab-kxwh (Hemlibra®) for hemophilia A with and without inhibitors. MASAC Document #268. Accessed December 19, 2022. https://www.hemophilia.org/sites/default/files/document/files/268_Emicizumab.pdf